RxDoctor Payments Data

Terry Lee, MD

Family Medicine · Monterey Park, CANPI 1184796104

Payments from drug & device makers

$19,273in general payments, 2019–2025

Across 799 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Gilead$2K
  • Amarin Pharma, Inc.$1K
  • Amgen$1K
  • AbbVie$1K
  • Boehringer Ingelheim$955
  • plus $9K from 43 others

What the payments were for

  • Food & beverage$19,03699%
  • Education$920%
  • Gifts$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,273 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$120,011
Medicare patients
265
Services billed
1,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$143,188
Janumet XrSitagliptin Phos/Metformin Hcl123$143,074
FarxigaDapagliflozin Propanediol123$133,508
JanuviaSitagliptin Phosphate107$122,241
ProliaDenosumab40$66,962
KerendiaFinerenone69$63,670
VascepaIcosapent Ethyl111$52,464
RybelsusSemaglutide25$47,325
EliquisApixaban60$41,818
VemlidyTenofovir Alafenamide17$32,668
TradjentaLinagliptin46$30,637
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$22,861
OzempicSemaglutide22$21,641
Icosapent Ethyl65$19,386
Jentadueto XrLinagliptin/Metformin Hcl24$14,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet Xr, Januvia$597$265,314230 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr, Glyxambi$955$202,997216 claims
AstraZenecaFarxiga, Breztri Aerosphere$4,126$156,370152 claims
Novo NordiskRybelsus, Ozempic$756$68,96647 claims
AmgenProlia$1,195$66,96240 claims
BayerKerendia$522$63,67069 claims
PfizerEliquis$369$41,81860 claims
GileadVemlidy$1,908$32,66817 claims
Lilly USA, LLCTrulicity$783$9,81211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →